EHA 9

Friday 11 June

Education Sessions | Lunch Debates | ESH-EHA Joint Symposium | Poster Session 1 | Satellite Symposia

EDUCATION SESSION
08.00 - 09.30 and 13.15 - 14.45,
Room Le Mont-Blanc / Le Cervin (Geneva Palexpo)

ACUTE LEUKEMIA

Chair:

R. Hehlmann (Medical Hospital Mannheim, Mannheim, Germany)

	A EUROPEAN NETWORK FOR AML A.K. Burnett (University Hospital Wales, Cardiff, Wales, United Kingdom)
	DEVELOPING A EUROPEAN NETWORK FOR ADULT ALL N. Gökbuget (University of Frankfurt, Frankfurt, Germany)
	THE NEED FOR EUROPEAN STANDARDS IN GENE EXPRESSION PROFILES IN AML B.D. Young (Cancer Research UK, London, United Kingdom)

EDUCATION SESSION
08.00 - 09.30 and 13.15 - 14.45, Room Le Jura (Geneva Palexpo)

SUPPORTIVE CARE: NEW APPROACHES FOR DIAGNOSIS AND TREATMENT OF INFECTIONS

Chair:

C. Cordonnier (Henri Mondor Hospital, Créteil, France)

	THE CHOICE OF EMPIRICAL THERAPY AND PROPHYLAXIS A. Del Favero (University of Perugia, Perugia, Italy)
	FUNGAL INFECTIONS: CURRENT DIAGNOSIS AND TREATMENT C. Cordonnier (Henri Mondor Hospital, Créteil, France)
	VIRAL INFECTIONS: CURRENT DIAGNOSIS AND TREATMENT P. Ljungman (Karolinska Institute, Stockholm, Sweden)

EDUCATION SESSION
08.00 - 09.30 and 13.15 - 14.45, Room D (Geneva Palexpo)

TRANSFUSION SAFETY

Chair:

J. Koistinen (Finnish Red Cross Blood Transfusion Service, Helsinki, Finland)

	EVOLUTION OF MICROBIAL SAFETY J. Barbara (National Blood Service, London, United Kingdom)
	HAEMOVIGILANCE PROCEDURE IN TRANSFUSION MEDICINE J.C. Faber (Luxembourg Red Cross, Luxembourg, Luxembourg)
	SAFETY ASPECTS OF BLOOD TRANSFUSION AND EUROPEAN LEGISLATION J. Koistinen (Finnish Red Cross Blood Transfusion Service, Helsinki, Finland)

EDUCATION SESSION
08.00 - 09.30 and 13.15 - 14.45, Room H (Geneva Palexpo)

IMMUNOTHERAPY

Chair:

A. Madrigal (The Anthony Nolan Research Institute, London, United Kingdom)

	IMMUNOTHERAPY WITH ALLOREACTIVE NATURAL KILLER CELLS IN HAPLOIDENTICAL HEMATOPOIETIC TRANSPLANTATION A. Velardi (Univeristy of Perugia, Perugia, Italy)
	IMMUNOTHERAPY WITH ALLOREACTIVE T-CELLS A. Madrigal (The Anthony Nolan Research Institute, London, United Kingdom)
	IMMUNOTHERAPY OF HEMATOLOGICAL MALIGNANCIES WITH DENDRITIC CELLS J.H.F. Falkenburg (University Medical Center Leiden, Leiden, The Netherlands)

EDUCATION SESSION
08.00 - 09.30 and 13.15 - 14.45, Room E (Geneva Palexpo)

RBC ERYTHROPOETIN PATHOPHYSIOLOGY

Chair:

M. Cazzola (University of Pavia Medical School, Pavia, Italy)

	ERYTHROPOIETIN PATHOPHYSIOLOGY AND ERYTHROPOIETIN DEFICIENCY ANEMIA M. Cazzola (University of Pavia Medical School, Pavia, Italy)
	EPOETIN-INDUCED AUTOIMMUNE PURE RED CELL APLASIA N. Casadevall (Hôpital Hôtel-Dieu, Paris, France)
	ERYTHROPOIETIN & ERYTHROPOIESIS: POLYCYTHEMIAS DUE TO DISRUPTION OF OXYGEN HOMEOSTASIS J.T. Prchal (Baylor College of Medicine, Houston, USA)

EDUCATION SESSION
10.00 - 11.30 and 15.15 - 16.45, Room A (Geneva Palexpo)

STEM CELLS

Chair:

W. Fibbe (Leiden University Medical Centre, Leiden, The Netherlands)

	NUCLEAR TRANSPLANTATION, EMBRYONIC STEM CELLS AND THE POTENTIAL FOR CELL THERAPY K. Hochedlinger (Whitehead Institute, Cambridge, USA)
	THE MOLECULAR BASIS OF STEM CELL SELF RENEWAL J. Krosl (Université de Montréal, Montreal, Canada)
	THE ROLE OF BONE MARROW STEM CELLS IN TISSUE VASCULARIZATION S. Rafii (Cornell University Medical College, New York, NY, USA)

EDUCATION SESSION
10.00 - 11.30 and 15.15 - 16.45, Room B (Geneva Palexpo)

CHRONIC MPD

Chair:

R. Skoda (Basel University Hospital, Basel, Switzerland)

	CHRONIC MYELOPROLIFERATIVE DISORDERS: MOLECULAR MARKERS AND PATHOGENESIS R. Skoda (Basel University Hospitals, Basel, Switzerland)
	MANAGEMENT OF THE MYELOPROLIFERATIVE DISORDERS: DISTINGUISHING DATA FROM DOGMA A.R. Green (Cambridge Institute for Medical Research, Cambridge, United Kingdom)
	FIP1L1-PDGFR _ IN HYPEREOSINOPHILIC SYNDROME AND MASTOCYTOSIS G. Gilliland (Harvard Institute of Medicine, Boston, USA)

EDUCATION SESSION
10.00 - 11.30 and 15.15 - 16.45, Room C (Geneva Palexpo)

EXPRESSION PROFILING: WHERE IS THE FIELD GOING?

Chair:

Ch. Willman (University of New Mexico, Albuquerque, NM, USA)

	BIOINFORMATICS J. Quackenbush (The Institute for Genomic Research, Rockville, MD, USA)
	PROTEOMICS D. Hochstrasser (Geneva University Hospital, Geneva, Switzerland)
	FROM LEUKEMIA GENOMICS TO PROGNOSTIC AND THERAPEUTIC TARGET VALIDATION Ch. Willman (University of New Mexico, Albuquerque, NM, USA)

EDUCATION SESSION
10.00 - 11.30 and 15.15 - 16.45,
Room Le Mont-Blanc / Le Cervin (Geneva Palexpo)

DIFFUSE LARGE B-CELL LYMPHOMA

Chair:

B. Coiffier (Centre Hospitalier Lyon-Sud, Pierre Benité, France)

	THE MOLECULAR HETEROGENEITY OF DIFFUSE LARGE B CELL LYMPHOMA R. Gascoyne (BC Cancer Agency, Vancouver BC, Canada)
	PET SCAN IN THE THERAPEUTIC STRATEGY C. Haioun (Hôpital Henri Mondor, Creteil, France)
	DOSE INTENSITY OR MONOCLONAL ANTIBODIES IN FIRST LINE TREATMENT B. Coiffier (Centre Hospitalier Lyon-Sud, Pierre Benité, France)

EDUCATION SESSION
10.00 - 11.30 and 15.15 - 16.45, Room Le Jura (Geneva Palexpo)

PLATELETS

Chair:

K.J. Clemetson (Theodor-Kocher-Institut der Universität, Bern, Switzerland)

	PLATELET RECEPTOR SIGNALLING K.J. Clemetson (Theodor-Kocher-Institut der Universität, Bern, Switzerland)
	MEASURING PLATELET FUNCTION? P. Harrison (Churchill Hospital, Oxford, United Kingdom)
	ANTIPLATELET AGENTS M. Cattaneo (University of Milano, Milano, Italy)

EDUCATION SESSION
10.00 - 11.30 and 15.15 - 16.45, Room D (Geneva Palexpo)

CONTROVERSIES IN TRANSFUSION COMPONENT THERAPY

Chair:

M. Contreras (Blood Transfusion Centre, London, United Kingdom)

	HAEMOVIGILANCE IN THE UNITED KINGDOM AND EUROPE D. Stainsby (National Blood Service Newcastle, Newcastle, United Kingdom)
	INTRAVENOUS IMMUNOGLOBULINS - TOO MANY INDICATIONS? U. Nydegger (Univeristy Hospital Bern, Bern, Switzerland)
	GRANULOCYTE TRANSFUSIONS - ARE THEY EFFECTIVE? T. Price (Puget Sound Blood Center, Seattle, USA)

EDUCATION SESSION
10.00 - 11.30 and 15.15 - 16.45, Room H (Geneva Palexpo)

GENES SWITCHING THEM ON AND OFF

Chair:

J. Melo (Imperial College London, London, United Kingdom)

	SWITCHING OFF ONCOGENIC SIGNALS IN CHRONIC MYELOID LEUKAEMIA J. Melo (Imperial College London, London, United Kingdom)
	RNA INTERFERENCE AS POWERFUL TOOL FOR GENE SILENCING A. Borkhardt (Dr. Von Haunersches Kinderspital, Munich, Germany)
	FLT3 TYROSINE KINASE AS A TARGET IN ACUTE LEUKEMIAS J. Griffin (Dana Farber Cancer Institute, Boston, USA)

EDUCATION SESSION
10.00 - 11.30 and 15.15 - 16.45, Room E (Geneva Palexpo)

RBC CONGENITAL ANEMIA

Chair:

D. Loukopoulos (Foundation For Biomedical Reseach, Athens, Greece)

	CONGENITAL DYSERYTHROPOIETIC ANEMIAS G. Tchernia (Laboratoire d’Hématologie, Le Kremlin-Bicêtre, France)
	VASO-OCCLUSION IN SICKLE-CELL ANEMIA: ROLE OF INTERACTIONS BETWEEN BLOOD CELLS AND ENDOTHELIUM J. Elion (Hôpital R. Debré, Paris, France)
	MOLECULAR PATHOLOGY OF THALASSEMIA INTERMEDIA Ph. Beris (Hôpital Cantonal Universitaire, Geneva, Switzerland)

LUNCH DEBATE
11.45 - 12.45, Room A (Geneva Palexpo)

DO WE AIM FOR TOO LOW A HEMOGLOBIN LEVEL AS A TRIGGER FOR TRANSFUSION?

Chair:

W.R. Mayr (University of Vienna, Vienna, Austria)

	YES M. Contreras (Blood Transfusion Centre, London, United Kingdom)
	NO G. Birgegard (University of Uppsala, Uppsala, Sweden)

LUNCH DEBATE
11.45 - 12.45, Room C (Geneva Palexpo)

GENE THERAPY FOR HEMOPHILIA, IS THIS APPROPRIATE IN AN ERA OF RECOMBINANT PRODUCTS?

Chair:

I. Pabinger (Medical Clinic I, Vienna, Austria)

	YES C. Negrier (Hôpital Edouard Herriot, Lyon, France)
	NO P. Giangrande (Churchill Hospital, Oxford, United Kingdom)

LUNCH DEBATE
11.45 - 12.45, Room Le Mont-Blanc / Le Cervin (Geneva Palexpo)

IS CURE THE TREATMENT GOAL FOR FOLLICULAR LYMPHOMA?

Chair:

A. Hagenbeek (University Medical Center Utrecht, Utrecht, the Netherlands)

	YES G. Salles (Centre Hospitalier Lyon-Sud, Pierre Benité, France)
	NO R. Marcus (Addenbrookes Hospital, Cambridge, United Kingdom)

Top

ESH-EHA JOINT SYMPOSIUM
11.30 – 13.00, Room D (Geneva Palexpo)

COMMUNICATION SKILLS
CONFLICTS AND COMPROMISES IN THE MANAGEMENT OF PATIENTS PURSUING COMPLEMENTARY THERAPIES; AN INTERACTIVE SESSION FOR HAEMATOLOGISTS

Chair:

S. Johnson (Taunton, United Kingdom)

Discrepancies in the conceptual framework with which doctors and patients view illness are a major source of difficulties in communication and in the satisfactory delivery of both specific medical treatments and broader types of health care. While it is possible to train doctors in the skills required to be able to communicate well with patients, little attention has been paid to examining the basic concepts with which patients understand the physical conditions from which they suffer. As a consequence it is often difficult to achieve a level of mutual understanding of medical problems which, if present, would be a sound basis for a partnership in the delivery of medical treatments. This degree of understanding of the underlying mechanisms of disease is one which is needed if patients are to be in a position to engage
realistically in decisions about treatment choice – for instance in making the transition from active to palliative treatment approaches. The current emphasis on obtaining informed consent to treatment in a context of providing comprehensive information to patients is also clearly dependent on a sound appreciation of the extent and limits within which patients
understand disease processes.

The perception patients have of their illness and appropriate treatment may also be significantly affected by conceptual frameworks which are likely to have a profound impact on the management of their disease. The assertion of Jehovah’s Witnesses that transfusion of blood or blood products is precluded by their religious beliefs is a recurrent difficulty for clinicians approaching many clinical situations but it is especially difficult when it impacts on the management of haematological malignancies. Patients are also increasingly willing to explore a wide range of complementary therapies which they may encounter through Internet searches or more direct contact with alternative therapists. It is understandable that patients should seek any means of improving their chances of cure, but the concurrent provision of conventional therapy and treatment based on unconventional interpretations
of the disease process may present very significant problems. It is sometimes difficult to negotiate with the patient and persuade them to accept established forms of treatment in the face of objections from the alternative therapist to the language and scientific basis on which medical therapy is
based.

Faculty
S. Johnson (Taunton, United Kingdom)
A. Cucuianu (Cluj Romania)
P. Brice (Paris, France)
A. Kiss (Basel, Switzerland
C. Rudin (Exeter, United Kingdom)

PROGRAM

	WELCOME: AIM OF MEETING S. Johnson (Taunton, United Kingdom)
	RULES OF ENGAGEMENT S. Johnson (Taunton, United Kingdom)

Case Study
A 32-year-old woman (a single mother with an 8-year-old son) was diagnosed eighteen months ago with diffuse large B-cell lymphoma IPI=3. She entered remission after six cycles of CHOP but relapsed in abdominal lymph nodes within six months. At this point she received two cycles of ifosfamide-based salvage chemotherapy with concurrent rituximab; the
disease proved to be chemosensitive and she proceeded to a BEAM autograft with six post-transplant doses of rituximab. Despite her apparent complete remission after high-dose therapy she has had some recurrence of her initial symptoms of fatigue and night sweats. A CT scan now shows progression of her abdominal lymph nodes, with compression of the left
ureter and hydronephrosis on that side. You intend to discuss the role of active palliation with her and explore entry into a Phase II trial involving gemcitabine and vinorelbine (she has no full siblings and because of her ethnic group a preliminary donor search has not revealed a good match on the national panel). She has come to Clinic for confirmation of the CT result and to discuss treatment with you, but is accompanied by her REIKI therapist whom you
have not met previously.

	CLINICAL CONSULTATION A. Cucuianu (Cluj, Romania)
	DISCUSSION AND FEEDBACK S. Johnson (Taunton, United Kingdom)
	CLINICAL CONSULTATION P. Brice (Paris, France)
	DISCUSSION AND FEEDBACK S. Johnson (Taunton, United Kingdom)
	THE WIDER IMPLICATIONS: INSIGHTS FROM MEDICAL ANTHROPOLOGY AND PSYCHO-SOMATIC MEDICINE A. Kiss (Basel, Switzerland) and C. Rudin (Exeter, United Kingdom)
	CONCLUSIONS S. Johnson (Taunton, United Kingdom)

Top

SATELLITE SYMPOSIUM SUPPORTED BY ROCHE, NAPP, MUNDIPHARMA, SUPERGEN INC., BIOENVISION AND ORTHO BIOTECH, A DIVISION OF JANSSEN-CILAG
18:30 – 20:30, Room B (Geneva Palexpo)

THE M.D. ANDERSON CANCER CENTER APPROACH TO PATIENTS WITH HEMATOLOGIC MALIGNANCIES

Chair:

M. Keating (The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA)

	18:30 – 18:50
	NEW DRUG DEVELOPMENT IN HEMATOLOGIC MALIGNANCIES S. O’Brien (The University of Texas, M.D. Anderson Cancer Center, Houston, Texas, USA)
	18:50 – 19:10
	INNOVATION IN THE MANAGEMENT OF AML AND ALL H. Kantarjian (The University of Texas, M.D. Anderson Cancer Center, Houston, Texas, USA)
	19:10 – 19:30
	EMERGING THERAPIES FOR CHRONIC LYMPHOCYTIC LEUKEMIA M. Keating (The University of Texas, M.D. Anderson Cancer Center, Houston, Texas, USA)
	19:30 – 19:50
	NOVEL APPROACHES TO PH-POSITIVE DISEASE J. Cortes (The University of Texas, M.D. Anderson Cancer Center, Houston, Texas, USA)
	19:50 – 20:10
	NEW TARGETS TO APPROACH, OLD PATHWAYS TO EXPLOIT W. Plunkett (The University of Texas, M.D. Anderson Cancer Center, Houston, Texas, USA)
	20:10 – 20:30
	INNOVATIVE APPROACHES TO THE TREATMENT OF LYMPHOMA A. Goy (The University of Texas, M.D. Anderson Cancer Center, Houston, Texas, USA)

SATELLITE SYMPOSIUM SUPPORTED BY PHARMION LTD
18:30 – 20:30, Room La Saleve (Geneva Palexpo)

EPIGENETICS IN HEMATOLOGY AND NOVEL THERAPEUTIC APPROACHES TO MDS

Chair:

P. Fenaux (Hôpital Avicenne, Service d’hematologie clinique, Bobigny, France)

	18:30 – 18:35
	CHAIRMAN’S INTRODUCTION P. Fenaux (Hôpital Avicenne, Service d’hematologie clinique, Bobigny, France)
	18:35 – 19:00
	EPIGENETICS: DNA HYPERMETHYLATION AND GENE SILENCING J. Herman (The Sidney Kimmel, Comprehensive Cancer Center, Johns Hopkins Comprehensive Cancer Center, Baltimore, Maryland, USA)
	19:00 – 19:10
	QUESTIONS AND ANSWERS
	19:10 – 19:30
	MDS: CURRENT TREATMENT OPTIONS G. Mufti (Guy’s King’s and St. Thomas’ School of Medicine, London, United Kingdom)
	19:30 – 19:55
	DEMETHYLATING AGENTS IN MDS: AZACITIDINE UPDATE P. Fenaux (Hôpital Avicenne, Service d’hematologie clinique, Bobigny, France)
	19:55 – 20:15
	AML IN THE ELDERLY PATIENT: MOLECULARLY TARGETED THERAPIES A.K. Burnett (University Hospital of Wales, Healthcare NHS Trust, Cardiff, United Kingdom)
	20:15 – 20:25
	QUESTIONS AND ANSWERS
	20:25 – 20:30
	CLOSING COMMENTS P. Fenaux (Hôpital Avicenne, Service d’hematologie clinique, Bobigny, France)
	20:30
	BUFFET DINNER

Top

POSTER SESSION I
17:00 - 18:30, Hall I (Geneva Palexpo)

	Lymphoma: Biological aspects and prognosis
	Lymphoma: Treatment with monoclonal antibodies
	Multiple Myeloma: Biological aspects
	ALL: Biology
	CLL: ZAP-70 and other markers mutational status
	CLL: Therapy
	AML Therapy
	Chronic Myeloid Leukemia
	Stem cell transplantation - Experimental
	Stem cell transplantation - Autologous
	Anticoagulation and thrombophilia
	Infectious complication
	Immune thrombocytopenic purpura
	Transfusion medicine and immunohematology
	Genetics lymphoid malignancies
	Cytokines / Growth factors
	Stem cells
	Genetic Leukemia I
	Genetic Leukemia II
	Anemia - Congenital
	Anemia - Thalassemias

NEW THIS YEAR: “POSTER-WALKS”

Unique full-three-day display of all posters

Poster walks will be organized during the official poster sessions.
Authors are requested to be present at the first poster of their poster
session, at the beginning of the presentation time, to attend the
“Poster-walks”. During these walks, an expert in the field will discuss
posters in the same poster session. Moderators and poster authors
will present and discuss each poster in a certain session, together
with interested Congress participants.

LYMPHOMA: BIOLOGICAL ASPECTS AND PROGNOSIS

001	CD10 AND BCL-2 EXPRESSION COMBINED WITH THE INTERNATIONAL PROGNOSTIC INDEX CAN IDENTIFY SUBGROUPS OF PATIENTS WITH DIFFUSE LARGE-CELL LYMPHOMA WITH VERY LOW AND VERY HIGH RISK I. Biasoli, J.C. Morais, A. Scheliga, C. Milito, S. Romano, M. Land, R. Schaffel, W. Pulcheri, N. Spector (Federal University of Rio de Janeiro, Rio De Janeiro, Brazil)
002	COMPARISON OF GENE EXPRESSION PROFILING BETWEEN MANTLE CELL LYMPHOMA IN LEUKEMIC PHASE AND NORMAL NAOEVE B-CELLS WITH OLIGONUCLEOTIDE MICROARRAYS E.G. Rizzatti, A.G. Araújo, M.H. Tavella, A.B. Garcia, D.A.P. Gallo, R. Proto- Siqueira, O.K. Okamoto, R.P. Falcão, M.A. Zago (School of Medicine of Ribeirão Preto, Ribeirão Preto, Brazil)

003	FISH IS THE BEST METHOD TO DETECT BCL2/IGH TRANSLOCATION IN FOLLICULAR LYMPHOMA AT DIAGNOSIS. A COMPARATIVE STUDY WITH CONVENTIONAL CYTOGENETICS, FISH AND PCR TECHNIQUES USING BIOMED-2 PRIMERS B. Espinet, B. Bellosillo, E. Gregori, V. Escurriol, M. Salido, L. Florensa, C. Pedro, C. Besses, S. Woessner, S. Serrano, F. Sole (Hospital del Mar, Barcelona, Spain)
004	ABSENCE OF MALT1 TRANSLOCATIONS IN MALT LYMPHOMAS OF THE SKIN B. Espinet, F. Gallardo, R.M. Puijol, T. Estrach, O. Servitje, S. Serrano, F. Sole (Hospital del Mar, Barcelona, Spain)
005	IMPROVED MOLECULAR DIAGNOSIS OF T(14;18) IN FOLLICULAR LYMPHOMAS: ROUTINE USE OF LONG-DISTANCE POLYMERASE CHAIN REACTION S. Vlachova, V. Prochazka, M. Luhovy, M. Divoka, T. Papajik, M. Jarosova, Z. Pikalova, K. Indrak (University Hospital, Olomouc, Czech Republic)
006	COMBINED ELEVATION OF IL-10, TNF-ALPHA- AND VEGF PLASMA LEVELS DISCRIMINATE SEVERAL GROUPS OF DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS WITH A MARKEDLY DIFFERENT OUTCOME E. Lech-Maranda, J. Bienvenu, A-L. Debard, S. Tartas, A-S. Michallet, C. Thieblemont, B. Coiffier, G. Salles (Medical University, Lodz, Poland)
007	INCREASED VASCULARIZATION PREDICTS FAVORABLE OUTCOME IN FOLLICULAR LYMPHOMA, AND IS NOT MEDIATED BY VEGF OR RELATED TO PROLIFERATION A. Koster, H. Tromp, J. Raemaekers, W. Leenders, M. MacKenzie, H. van Krieken (University Medical Centre Nijmegen, Nijmegen, The Netherlands)
008	ABERRANT SOMATIC HYPERMUTATION IS INVOLVED IN THE MOLECULAR PATHOGENESIS OF POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS C.M. Cerri, D. Rossi, D. Capello, G. Muti, E. Berra, C. Deambrogi, C. Vendramin, S. Franceschetti, E. Morra, A. Rambaldi, M. Paulli, G. Gaidano (University of Eastern Piedmont, Novara, Italy)
009	STROMA AND INFILTRATING INFLAMMATORY CELLS BUT NOT THE TUMOR CELLS ARE THE SOURCE OF APRIL/TALL-2 EXPRESSION IN HUMAN MALIGNANT LYMPHOPROLIFERATIVE DISORDERS. J. Schwaller, P. Mhawech-Fauceglia, C. Cerato, P. Scneider, J. Tschopp, O. Donze, B. French, B. Huard (Geneva University Medical School, Geneva, Switzerland)
010	CELL CYCLE REGULATORY GENES EXPRESSION IN DIFFUSE LARGE B-CELL LYMHOMAS C. Kontsioti, V. Pappa, D. Rontogianni, S. Papageorgiou, E. Kavada, T. Economopoulos, J. Dervenoulas, E. Papageorgiou, S. Raptis (Attikon University General Hospital, Athens, Greece)

011	IF IT IS IN THE MARROW, IT IS ALSO IN THE BLOOD. CONCORDANCE BETWEEN MARROW AND BLOOD EXAMINATIONS IN 826 PAIRED SAMPLES FROM 561 LYMPHOMA PATIENTS E. Muratori, A. Calleri, C. Rabascio, P. Mancuso, G. Martinelli, F. Bertolini (European Institute of Oncology, Milan, Italy)
012	THE ‘CUTANEOUS VARIANT’ EXHIBITS A FAVORABLE CLINICAL BEHAVIOR WITH RESPECT TO OTHER CLINICAL PRESENTATIONS OF INTRAVASCULAR LYMPHOMA (IVL): THE I.E.L.S.G. EXPERIENCE ON 40 CASES A.J.M. Ferreri, A.J.M. Ferreri, E. Campo, F. Ilariucci, A. Ambrosetti, J.F. Seymour, R. Willemze, S. Dell’Oro, E. Zucca, M.A. Piris, P. Iuzzolino, M. Lestani, M. Ungari, N. Frungillo, C. Doglioni, M. Ponzoni (San Raffaele Scientific Institute, Milan, Italy)
013	IGVH MUTATIONAL STATUS, GENE USAGE AND IMMUNOPHENOTYPE IN MANTLE CELL LYMPHOMA/LEUKAEMIA. C. Matthews, M.A. Catherwood, T.C.M. Morris, H.D. Alexander (Belfast City Hospital, Belfast, Northern Ireland)
014	DETECTION OF TCR-GAMMA AND TCR-DELTA GENE REARRANGEMENT BY PCR IN SKIN AND PERIPHERAL BLOOD OF PATIENTS WITH EARLY MYCOSIS FUNGOIDES. G. Goteri, A.R. Scortechini, S. Rupoli, S. Pulini, A. Tassetti, S. Barulli, A. Filosa, I. Cataldi, G. Brandozzi, D. Brancorsini, A.M. Offidani, M. Ottaviani, G. Tucci, S. Serresi, R. Capretti, P. Leoni (Department of Neurosciences, Ancona, Italy)
015	ROLE OF CD38 EXPRESSION IN B-CELL NON-HODGKIN’S LYMPHOMAS IN LEUKEMIC PHASE: CLINICO-BIOLOGICAL CORRELATIONS A. Pulsoni, A.R. Guarini, M.S. De Propris, N. Frattarelli, E. Cavalieri, V. Gianfelici, F. Mancini, F. Cucchi, F.R. Mauro, R. Foà (University “La Sapienza”, Rome, Italy)

LYMPHOMA: TREATMENT WITH MONOCLONAL ANTIBODIES

016

FRACTIONATED RADIOIMMUNOTHERAPY WITH DOTACONJUGATED, 90Y-RADIOLABELED, HUMANIZED ANTI-CD22 MONOCLONAL ANTIBODY (EPRATUZUMAB) APPEARS SAFE AND EFFICACIOUS ACROSS NHL PATIENT GROUPS
J-F. Chatal, J. Harousseau, F. Griesinger, J. Meller, C. Renner, C.M. Kirsch, R. Naumann, J. Kropp, M.U. Qidwai, J. Lateiner, J. Kovacs, C. Ding, W.A. Wegener, I.D. Horak, D.M. Goldenberg (Institut de Biologie, INSERM, Nantes, France)

017

RITUXIMAB IN PATIENTS WITH HAIRY CELL LEUKEMIA RELAPSING AFTER TREATMENT WITH 2-CHLORODEOXYADENOSINE (2-CDA)
R.Z. Zenhäusern, A. Von Rohr, K. Rufibach, M. Solenthaler, S. Meyer-Monard, A. Gratwohl, U. Hess, T. Cerny, M. Bargetzi, T. Kovacsovic, L. Leoncini, A. Tobler (Inselspital, Bern, Switzerland)

018	HIGH CLINICAL AND MOLECULAR RESPONSE AFTER A BRIEF CHEMO-IMMUNOTHERAPY FND + RITUXIMAB IN ELDERLY PATIENTS WITH DE NOVO ADVANCED STAGE FOLLICULAR LYMPHOMA (FL) U. Vitolo, C. Boccomini, M. Ladetto, E. Pogliani, R. Rota Scalabrini, C. Tarella, C. Castellino, M. Aglietta, M. Astolfi, B. Botto, A. Carpaneto, P. Corradini, A. Darbesio, A. De Crescenzo, A. Levis, A.M. Liberati, S. Morandi, L. Orsucci, L. Rigacci, F. Rossini, A. Tonso, E. Gallo (SC Ematologia 2, Torino, Italy)
019	SUBSEQUENT THERAPY FOR NON-HODGKIN’S LYMPHOMA IS FEASIBLE AFTER RADIOIMMUNOTHERAPY WITH YTTRIUM-90 IBRITUMOMAB TIUXETAN (ZEVALIN(R)) R.S. Schilder, S.M. Ansell, P.C. Pieslor, L.I. Gordon, C. Emmanouilides, M.S. Czuczman, H. Wang, T.E. Witzig, M.W. Saville, A. Molina (Fox Chase Cancer Center, Philadelphia, USA)
020	A PHASE I TRIAL OF TWO SEQUENTIAL DOSES OF ZEVALIN RADIOIMMUNOTHERAPY FOR RELAPSED LOW-GRADE B-CELL NON-HODGKIN’S LYMPHOMA G.W. Wiseman, T.E. Witzig (Mayo Clinic, Rochester, USA)
021	RITUXIMAB PLUS CLADRIBINE IN HEAVILY PRETREATED LOWGRADE LYMPHOMA T. Robak, P. Smolewski, H. Urbanska-Rys, J. Gora-Tybor, J.Z. Blonski, M. Kasznicki (Medical University of Lodz, Lodz, Poland)
022	COMBINATION OF THE ANTI-CD20 ANTIBODY RITUXIMAB WITH SEQUENTIAL HIGH-DOSE CHEMOTHERAPY FOLLOWED BY AUTOLOGOUS STEM CELL SUPPORT IN RELAPSED AND REFRACTORY AGGRESSIVE NON-HODGKIN’S LYMPHOMA M. Sieniawski, J.O. Staak, H. Scheuss, J.P. Glossmann, V. Diehl, A. Engert, A. Josting (University Hospital Cologne, Cologne, Germany)
023	EARLIER YTTRIUM-90 IBRITUMOMAB TIUXETAN (ZEVALIN(R)) TREATMENT IN PATIENTS WITH PREVIOUSLY-TREATED B-CELL NON-HODGKIN’S LYMPHOMA: HIGHER RESPONSE RATES AND LONGER DURATIONS OF RESPONSE C. Emmanouilides, J.L. Murray, K. Vo, T.E. Witzig, M. Darif, R.J. Schilder, I. Flinn, L.I. Gordon, G. Wiseman, P. Multani, A. Molina (UCLA, Los Angeles, USA)
024	DELAYED-ONSET PERIPHERAL BLOOD CYTOPENIA AFTER RITUXIMAB. FREQUENCY AND RISK FACTOR ASSESSMENT IN A CONSECUTIVE SERIES OF 77 TREATMENTS C. Cattaneo, P. Spedini, G. Ruggeri, A. Tucci, A. Re, E. Borlenghi, E. Damiani, G. Pelizzari, F. Facchetti, G. Rossi (Spedali Civili, Brescia, Italy)
025	COMBINATION OF EPRATUZUMAB PLUS RITUXIMAB IN RELAPSED/REFRACTORY INDOLENT AND AGGRESSIVE NHL: MULTI-CENTER, PHASE-II UPDATE J. Strauss, J. Strauss, A. Lister, F. Morschauser, M. Gramatzki, P. Solal-Celigny, P.L. Zinzani, A. Engert, B. Coiffier, D.Hoelzer, W.A. Wegener, J. Kovacs, M.U. Qidway, C. Ding, I.D. Horak, D.M. Goldenberg (St. Bartholomew’s Hospital, London, United Kingdom)

026	ANALYSIS OF LONG-TERM RESPONDERS: DURABLE REMISSIONS WITH YTTRIUM-90 IBRITUMOMAB TIUXETAN (ZEVALIN(R)) RADIOIMMUNOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN’S LYMPHOMA C. Emmanouilides, T.E. Witzig, A. Molina, L.I. Gordon, R.J. Schilder, I. Flinn, M. Czuczman, H. Wang, C. Theuer, G. Wiseman (UCLA, Los Angeles, USA)
027	RITUXIMAB, GEMCITABINE AND OXALIPLATIN (R-GEMOX): A PROMISING REGIMEN FOR REFRACTORY/RELAPSED B-CELL LYMPHOMA T. El Gnaoui, B. Joly, J. Dupuis, K. Belhadj, A. Rahmouni, C. Copie-Bergman, A. Allain, I. Tabah-Fisch, F. Reyes, C. Haioun (Henri Mondor, Créteil, France)
028	CNOP VS. CNOP-RITUXIMAB VS. RITUXIMAB ALONE AS FIRST LINE THERAPY FOR INDOLENT NON-HODGKIN LYMPHOMA (INHL): PRELIMINARY DISEASE-FREE/OVERALL SURVIVAL ANALYSIS S. Baltazar, G. Tripp, E. Baez, S. Rivas, L. Solís, G. Ignacio, J. Duque, O. Garcés, B. Rubio, J.L. Delgado, P. Rodriguez, H. Castillo, G. Cervantes, B. Batista, J.O. Talavera, M.E.E. Rubio-Borja (IMSS # 25, Monterrey N.L., Apodaca, Nvo Leon, Mexico)
029	DELAYED SEVERE NEUTROPENIA AFTER RITUXIMAB THERAPY IN 12 OUT OF 282 PATIENTS WITH NON HODGKIN’S LYMPHOMA TREATED IN A SINGLE INSTITUTION. A RARE ADVERSE EVENT OF UNKNOWN MECHANISM K. Belhadj, K. Doghmi, K. Belhadj, T. El Gnaoui, B. Joly, K. Lee, A. Plonquet, H. Jouault, C. André, F. Reyes, C. Haioun (Henri Mondor, Créteil, France)

MULTIPLE MYELOMA: BIOLOGICAL ASPECTS

030	SOCS1 AND SHP1 HYPERMETHYLATION IN MULTIPLE MYELOMA: IMPLICATIONS FOR EPIGENETIC ACTIVATION OF THE JAK/STAT PATHWAY C.S. Chim, T.K. Fung, W.C. Cheung, R. Liang, Y.L. Kwong (Queen Mary Hospital, Hong Kong, Hongkong)
031	EXPRESSION OF ADHESION MOLECULE CD58 (LFA-3) ON CD138HIGH AND CD138LOW CELLS IN MULTIPLE MYELOMA. R. Poglod, J. Kopec-Szlezak, M. Kraj, U. Sokolowska, B. Kruk (Institute of Hematology and Blood Trans, Warsaw, Poland)
032	EXPRESSION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND CD31 IN HUMAN MYELOMA CELLS. POTENTIAL RELATION TO DISEASE PROGRESSION AND TREATMENT RESPONSE S. Lifshits, T. Yermiahu, M. Kafka, O. Shpilberg, D. Benharroch, G. Shubinsky (Soroka University Medical Center, Beer-Sheva, Israel)
033	A ROLE FOR RHAMM IN MITOTIC INTEGRITY AND MYELOMAGENESIS A. Maxwell, T. Reiman, J.J. Keats, A.R. Belch, L.M. Pilarski (Cross Cancer Institute, Edmonton, Canada)

034	ASSOCIATION OF CYTOKINE GENES POLYMORPHISMS WITH MULTIPLE MYELOMA E. Yakupova, D.Kh. Kalimullina, B.A. Bakirov, T.V. Victorova (Institute of biochemistry and genetics, Ufa, Russian Federation)
035	MULTIPROBE INTERPHASE CYTOGENETICS DEFINES TWO SUBGROUPS OF MULTIPLE MYELOMA J. Bila, F.W. Cremer, I. Buck, M. Kartal, D. Hose, A. Mˆbus, M. Brough, F. Bellos, M. Moos, H. Goldschmidt, A. Jauch (University of Heidelberg, Heidelberg, Germany)
036	PRE-TRANSPLANT VEGF LEVELS IN MULTIPLE MYELOMA ARE PREDICTIVE FOR PROGRESSION FREE SURVIVAL. M.C. Politou, E. Terpos, D. Crawley, R. Szydlo, S. Avery, E. Olavarria, E. Kanfer, J.M. Goldman, J.F. Apperley, A. Rahemtulla (Imperial College Faculty of Medicine, London, United Kingdom)
037	HIGH INCIDENCE OF MONOCLONAL B-CELL DISEASE (MCBD) IN SIBLINGS (SIBS) OF PATIENTS (PTS) WITH MULTIPLE MYELOMA (MM) B. Roth, D. Behringer, J. Finke, M. Engelhardt (University Hospital Freiburg, Freiburg, Germany)
038	VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND ITS SOLUBLE RECEPTORS VEGFR-1 AND VEGFR-2 IN THE SERUM OF PATIENTS WITH MULTIPLE MYELOMA H.R. Urbanska-Rys, A. Wierzbowska, A. Krawczynska, T. Robak (Copernicus Memorial Hospital, Lodz, Poland)
039	SERUM LEVELS OF MIP-1-ALPHA- ARE USEFUL FOR STUDY OF BONE DISEASE IN MULTIPLE MYELOMA (MM) AND DIFFERENTIATION FROM MONOCLONAL GAMMOPATHY OF UNKNOWN SIGNIFICANCE (MGUS) AND BENIGN OSTEOPOROSIS (BO) J. Hernandez, R.M. Fisac, C. Olivier, J.A. Queizan, B. Suquia, J. Garcia-Frade, J.A. Portero, R. Lopez, R. Cuello, J.F. San Miguel (Hospital General de Segovia, Segovia, Spain)
040	T CELLS SUPPORT OSTEOCLASTOGENESIS IN AN IN VITRO MODEL DERIVED FROM HUMAN MULTIPLE MYELOMA BONE DISEASE S. Colucci, G. Brunetti, R. Rizzi, G. Mori, G. Colainanni, A. Liso, S. Capalbo, V. Liso, A. Zallone, M. Grano (Policlinico di Bari, Bari, Italy)
041	PRENYLATION INHIBITORS ALTER MULTIPLE MYELOMA CELL BIOLOGY M.A. Morgan, T. Sebil, A. Ganser, C.W.M. Reuter (Hannover Medical School, Hannover, Germany)
042	THE ACTIVATION OF THE PI3K-AKT PATHWAY IS NOT SUFFICIENT TO PROVIDE LONG TERM SURVIVAL OF HUMAN MALIGNANT PLASMA CELLS A. Guenther, F. Bakker, R. Burger, M. Gramatzki (University of Erlangen, Erlangen, Germany)

043	RELATIONSHIP BETWEEN POLYMORPHISMS OF METHYLEN TETRAHYDROFOLATE REDUCTASE (MTHFR) AND SUSCEPTIBILITY TO MULTIPLE MYELOMA P. Chiusolo, G. Reddiconto, A. Fiorini, G. Farina, L. Laurenti, R. Putzulu, M. Palladino, S. Bellesi, F. Sorà, E. Rossi, M. Tarnani, A. Di Mario, V. De Stefano, G. Leone, S. Sica (Catholic University, Rome, Italy)
044	SERUM FREE LIGHT CHAINS ARE A SENSITIVE MARKER OF SEROLOGICAL REMISSION IN MULTIPLE MYELOMA PATIENTS S.D. Reid, M.T. Drayson, G.P. Mead, B. Augustson, S. Roberts, A.R. Bradwell (The Binding Site Ltd, Birmingham, United Kingdom)
045	GENE EXPRESSION PROFILING OF PLASMA CELL DYSCRASIAS REVEALS MULTIPLE MYELOMA MOLECULAR HETEROGENEITY M. Mattioli, L. Agnelli, S. Fabris, L. Baldini, F. Morabito, S. Bicciato, D. Verdelli, D. Intini, L. Nobili, V. Callea, C. Stelitano, A.T. Maiolo, F. Bonino, L. Lombardi, A. Neri (Ospedale Maggiore IRCCS Milano, Milano, Italy)
046	INCREASED RISK FOR MULTIPLE MYELOMA IN INDIVIDUALS WITH THE HOMOZYGOUS 66GG POLYMORPHISM OF THE METHIONINE SYNTASE REDUCTASE (MTRR) GENE M.C. Ozelo, C.S.P. Lima, M.M. Ortega, R.C. Araujo, C.A. de Souza, I. Lorand-Metze, J.M. Annichino-Bizzacchi, F.F. Costa (State University of Campinas, Campinas, Brazil)
047	OPG AND SRANKL IN SERUM OF UNTREATED MULTIPLE MYELOMA (MM) PATIENTS M-C. Kyrtsonis, T.P. Vassilakopoulos, A. Papadogiannis, T. Tzenou, M.N. Dimopoulou, M.P. Siakantaris, S.I. Kokoris, E.M. Dimitriadou, E.M. Dimitriadou, K. Anargyrou, G.A. Pangalis (University of Athens, Athens, Greece)
048	SERUM SOLUBLE SYNDECAN-1 (S-SYND-1), INSULIN LIKE GROWTH FACTOR (IGF-1) AND MACROPHAGE INFLAMMATORY PROTEIN-1 ALPHA (MIP-1A) IN UNTREATED MULTIPLE MYELOMA PATIENTS. RELATIONSHIP WITH PROGNOSIS M-C. Kyrtsonis, T.P. Vassilakopoulos, A. Papadogiannis, T. Tzenou, M.N. Dimopoulou, M.P. Siakantaris, S.I. Kokoris, E.M. Dimitriadou, K. Anargyrou, N.A. Vyniou, P. Korkolopoulou, G.A. Pangalis (University of Athens, Athens, Greece)

ALL: BIOLOGY

049	REAL-TIME QUANTITATIVE PCR DETECTION OF WT1 GENE TRANSCRIPTS IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA J.S. Chen, T.Y. Chen, Ch.Ch. Hsiao, J.M. Sheen, C.N. Cheng (National Cheng Kung University Hospital, Tainan, Taiwan)

050	ANALYSIS OF BONE MARROW LYMPHOPOIESIS IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA DURING AND AFTER THE CHEMOTHERAPY G. Shubinsky, E. Israel, S. Atamna, H. Chermoshnuk, I. Dulman, T. Yermiahu, O. Shpilberg, I. Levi, J. Kapelushnik (Soroka University Medical Center, Beer-Sheva, Israel)
051	SYNERGISTIC CYTOTOXIC EFFECT OF RAPAMYCIN IN COMBINATION WITH PURINE NUCLEOSIDE ANALOGUES ON PRE-B ACUTE LYMPHOBLASTIC LEUKEMIA CELLS P. Smolewski, D. Wierzbicka, S. Piersanti, A. Traverso, B. Cebula, L. Teodori, T. Robak (Medical University of Lodz, Lodz, Poland)
052	VARIATIONS IN THE RECOMBINATION ACTIVATING GENES (RAG1/2) IN RELATION TO SUSCEPTIBILITY TO CHILDHOOD T-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA G.M. Taylor, H.P. O’Brien, J.M. Birch, O.B. Eden (University of Manchester, Manchester, United Kingdom)
053	MEK INHIBITOR IN PRIMARY ADULT ACUTE LYMPHOBLASTIC LEUKEMIA CELLS: OPPOSITE REGULATION OF EXTRACELLULAR SIGNAL-REGULATED KINASE-1/2 (ERK) AND P21CIP-1/WAF1 C. Gregorj, M.T. Petrucci, M.C. Scerpa, F. De Cave, M.R. Ricciardi, C.M. Precupanu, A. Vitale, G. Cimino, M. Mancini, M. Vignetti, M. Milella, M. Andreeff, F. Mandelli, R. Foà, A. Tafuri (Institute of Hematology, Rome, Italy)
054	ZAP-70 IS EXPRESSED IN NORMAL B-CELLS OF IMMATURE PHENOTYPE AND IN SOME B ACUTE LYMPHOBLASTIC LEUKEMIAS M. Crespo, N. Villamor, F. Bosch, E. Giné, E. Campo, E. Montserrat (Hospital Clinic, Barcelona, Spain)
055	HISTONE DEACETYLASE INHIBITORS ARE ABLE TO CHANGE LEUKAEMIA-SPECIFIC PHENOTYPE OF TEL/AML1-POSITIVE LEUKAEMIC CELLS J. Madzo, J. Starkova, M. Vaskova, T. Kalina, J. Trka (CLIP, Charles University, Prague, Czech Republic)
056	SHP-2 AND RAS FUNCTION IN INFANT ALL S. Martinelli, G. Cazzaniga, L. Corral, A. Leszl, M.G. Dell’Oro, C. Beretta, M. Spinelli, G. Fazio, B. Scicchitano, G. Basso, G. De Rossi, M. Tartaglia, A. Biondi (Istituto Superiore di Sanità, Roma, Italy)
057	EXPRESSION OF THE PRE-T CELL RECEPTOR ALPHA CHAIN IN ACUTE LYMPHOBLASTIC LEUKEMIA CELL LINES AND ITS POTENTIAL ROLE AS A THERAPEUTIC TARGET P. Ivanyi, W. Piao, U. Krug, J. Lauber, K. Steube, A. Ganser, A. Franzke (Hannover Medical School, Hannover, Germany)
058	UPREGULATION OF ASPARAGINE SYNTHETASE FAILS TO AVERT CELL CYCLE ARREST INDUCED BY L-ASPARAGINASE IN TEL/AML1-POSITIVE LEUKEAMIC CELLS J. Starkova, O. Krejci, B. Otova, J. Madzo, O. Hrusak, J. Stary, J. Trka (Childhood Leukaemia Investigation Prague, Prague, Czech Republic)

059	INCIDENCE AND SIGNIFCIANCE OF 12P13/ETV6 DELETION IN 269 ADULT ACUTE LYMPHOBLASTIC LEUKEMIA ENROLLED IN THE ALL 0496 AND 2000 GIMEMA TRIAL C.A. Cuneo, P. Agostini, A. Bardi, E. Tammiso, M. Mancini, M. Nanni, A. Vitale, L. Melillo, G. Perla, A. Santoro, F. Di Raimondo, F. Ronco, C. Mecucci, R. Foà, G. Castoldi, I. Attolico (University of Ferrara, Ferrara, Italy)
060	MYELOID ANTIGEN EXPRESSION IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA: IMPACT ON PROGNOSIS A. Vitale, A. Guarini, C. Ariola, F. Paoloni, M. Vignetti, F. Mandelli, R. Foà (University “La Sapienza”, Rome, Italy)

CLL: ZAP-70 AND OTHER MARKERS MUTATIONAL STATUS

061	PH CHROMOSOME-POSITIVE CML PATIENT WITH SUPPURATIVE PERIODONTITIS DURING TREATMENT WITH IMATINIB (STI571) M.G. Mele, A. Tartarone, G. Romano, M.L. Vigliotti, R. Matera, C. Musto, A.M. Capobianco, M. Coccaro, N. Di Renzo (Regional Hospital, Rionero In Vulture, Italy)
062	CD38 EXPRESSION AND NF-KB ACTIVITY IN B-CLL: EFFECT OF TGF-BETA MODULATION W. Barcellini, F.G. Imperiali, A. Zaninoni, E. Fermo, A. Zanella (IRCCS Ospedale Maggiore Policlinico, Milan, Italy)
063	VASCULAR ENDOTHELIAL GROWTH FACTOR IN PATIENTS WITH B- CHRONIC LYMPHOCYTIC LEUKEMIA. ASSOCIATION WITH THE STAGE AND OTHER PROGNOSTIC MARKERS OF THE DISEASE E. Kalagiakou, C. Belessi, E. Samaridis, K. Vallianatou, E. Manioudaki, G. Erotokritou, M. Ioannidou, E. Vigla, S. Kathrepti, M. Papaefstratiou, G. Kapari, A. Parasi, N. Laoutaris (Hematology Dept General hospital Nikea, Athens, Greece)
064	IDENTIFICATION OF NOVEL MARKER GENES FOR B-CELL CHRONIC LYMPHOCYTIC LEUKAEMIA S. Grund, B. Olsson, M. Jernas, S. Jacobsson, B. Swolin, L. Carlsson, H. Wadenvik (Sahlgrenska University Hospital, Göteborg, Sweden)
065	DETECTION OF ZAP-70 BY FLOW CYTOMETRY USING THE HIGHLY FLUORESCENT ALEXA FLUOR DYE IN CELLS FROM PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL) N.I. Folarin, R.J. Baker, V. Duke, B.C. Yogashangary, C. Vadikolia, M.W. Lowdell, R.G. Wickremasinghe, A.V. Hoffbrand, A. Nathwani, A.E. Virchis, A.B. Mehta, L. Foroni, K. Ganeshaguru (Royal Free & UC Medical School, London, United Kingdom)
066	A NOVEL FLOW CYTOMETRY ANALYSIS METHOD FOR THE QUANTITATION OF ZAP-70 EXPRESSION IN B-CLL CELLS S. Kay, M. Pick, Y. Herishanu, O. Rogowsky, S. Baron, E. Naparstek, A. Polliack, V. Deutsch (Tel Aviv Sourasky Medical Center, Tel Aviv, Israel)

067	INTEGRITY OF THE DNA SOMATIC HYPERMUTATION (SHM) MACHINERY IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) CELLS G. Giné, M. Crespo, F. Bosch, N. Villamor, E. Montserrat (Hospital Clinic of Barcelona, Barcelona, Spain)
068	CCR7 RECEPTOR EXPRESSION IS GREATER IN ZAP70 POSITIVE CLL-B CELLS AND IS ASSOCIATED WITH GREATER RESPONSIVENESS TO CCLS 19 AND 21. S.J. Richardson, J.A. Copplestone, A.G. Prentice (Derriford Hospital, Plymouth, United Kingdom)
069	VH GENE USAGE AND CHARACTERISITICS DIFFERS IN GERMLINE AND MUTATED B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA TO REVEAL TWO DIESEASE GROUPS V.M. Duke, B.C. Yogashangary, D. Gandini, P.D. Sherrington, K. Lin, K. Ganeshaguru, A. Nathwani, A.E. Virchis, A.B. Mehta, A.V. Hoffbrand, L. Foroni (Royal Free & University College Hospital, London, United Kingdom)
070	BIOMED-2 STANDARDISED PRIMERS AND PROTOCOL FOR ROUTINE ANALYSIS OF IGVH MUTATIONAL STATUS OBVIATE THE NEED FOR SURROGATE MARKERS IN B-CLL C. Matthews, M.A. Catherwood, T.C.M. Morris, H.D. Alexander (Belfast City Hospital, Belfast, Northern Ireland)
071	ZAP-70 OVEREXPRESSION IN T-CELLS OF B-CLL PATIENTS CORRELATES WITH INCREASED LEVELS IN B-CLL CELLS Y. Herishanu, S. Kay, M. Pick, O. Rogowsky, E. Naparstek, V. Deutsch, A. Polliack (Tel Aviv Sourasky Medical Center, Tel-Aviv, Israel)
072	ZAP-70 EXPRESSION IN CHRONIC LYMPHOCYTIC LEUKEMIA: FLOW CYTOMETRY, IMMUNOCYTOCHEMISTRY AND WESTERN BLOT ANALYSIS, AND CORRELATION WITH THE IGVH MUTATIONAL STATUS A. Guarini, M.S. De Propris, S. Intoppa, S. Masi, M.L. Milani, C. Ariola, F.R. Mauro, M. Gentile, E. Ghia, R. Foà (University “La Sapienza”, Rome, Italy)
073	ZAP-70 EXPRESSION IN B CHRONIC LYMPHOCYTIC LEUKAEMIA (B-CLL): MULTIPARAMETER FLOW CYTOMETRY OR IMMUNOCYTOCHEMISTRY? D. Dubois, M. Truchan-Graczyk, A. Godon, A. Tanguy-Schmidt, M.C. Rousselet-Chapeau, N. Ifrah, M. Zandecki, F. Genevieve (CHU of Angers, Angers, France)

CLL: THERAPY

074	FLUDARABINE AS INDUCTION THERAPY FOR CHRONIC LYMPHOCYTIC LEUKAEMIA: A SYSTEMIC REVIEW AND META-ANALYSIS. C.L. Tan, Y.C. Linn, Q. Zhu, M. Samuel, E. Chan (Singapore General Hospital, Singapore, Singapore)

075	ALEMTUZUMAB (CAMPATH(R), MABCAMPATH(R)) CONSOLIDATION AFTER FLUDARABINE PHOSPHATE AND CYCLOPHOSPHAMIDE SECOND-LINE CHEMOTHERAPY FOR PROGRESSIVE CHRONIC LYMPHOCYTIC LEUKEMIA L. Orsucci, P. Francia di Celle, A. Stacchini, L. Bergui, C. Boccomini, B. Botto, A. Chiappella, L. Godio, P. Pregno, E. Gallo, U. Vitolo (ASO S. Giovanni Battista, Turin, Italy)
076	CANNABINOIDS AS POTENTIAL ANTILEUKEMIC AGENTS M. Damri, O. Shpilberg, I. Nathan (Soroka University Medical Center, Beer Sheva, Israel)
077	IMMUNOTHERAPY OF B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA WITH AUTOLOGOUS IRRADIATED LEUCAEMIC CELLS AND BCG I. Hus, J. Kawiak, J. Rolinski, J. Tabarkiewicz, J. Tabarkiewicz, K. Wojas, A. Kosek, E. Wasik-Szczepanek, A. Dmoszynska (Medical University Lublin, Lublin, Poland)
078	INTERIM SAFETY SUMMARY OF ALEMTUZUMAB (CAMPATH(R), MABCAMPATH(R)) VS CHLORAMBUCIL AS FRONT-LINE THERAPY FOR PATIENTS WITH PROGRESSIVE B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA J. Mayer, T. Robak, A. Skotnicki, B. Jaksic, V. Vukovic, S. Weitman (University Hospital Brno, Brno, Czech Republic)
079	PENTOSTATIN AND RITUXIMAB COMBINATION FOR TREATMENT OF RELAPSED/REFRACTORY HAIRY CELL LEUKAEMIA - A REPORT OF 3 CASES N. Osuji, I. Del Giudice, N. Parry-Jones, E. Matutes, C. Dearden, D. Catovsky (Royal Marsden/Institute Cancer Research, London, United Kingdom)
080	LOW DOSE ORAL FLUDARABINE PLUS CYCLOPHOSPHAMIDE IN ELDERLY PATIENTS WITH CHRONIC LYMPHOPROLIFERATIVE DISORDERS A. Fabbri, M. Lenoci, A. Gozzetti, D. Raspadori, G. Marotta, F. Forconi, F. Lauria (Unit of Hematology/University of Siena, Siena, Italy)
081	ORAL GANCICLOVIR AS PRE-EMPTIVE TREATMENT IN PATIENTS WITH CMV REACTIVATION DURING ALEMTUZUMAB TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA L. Laurenti, P. Piccioni, P. Cattani, A. Cingolani, P. Chiusolo, M. Tarnani, A. Fiorini, G. Reddiconto, S. De Matteis, G. Fadda, D. Efremov, S. Sica, G. Leone (Policlinico A. Gemelli, Roma, Italy)
082	CAMPATH 10 MG IN PRETREATED CLL PATIENTS L. Laurenti, P. Piccioni, M. Tarnani, P. Chiusolo, M.G. Garzia, G. Zini, G. Farina, C. Rumi, N. Piccirillo, S. Sica, G. Leone (Policlinico A. Gemelli, Roma, Italy)
083	ALEMTUZUMAB AS FIRST-LINE THERAPY IN B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (B-CLL): LONG-TERM FOLLOW-UP OF CLINICAL EFFECTS, INFECTIOUS COMPLICATIONS, AND RISK OF RICHTER TRANSFORMATION (RT) C. Karlsson, S. Norin, J. Lundin, E. Kimby, H. Mellstedt, B. Sander, A. Porwit-MacDonald, A. Osterborg (Karolinska University Hospital, Stockholm, Sweden)

084

CYTOTOXIC T CELL CLONES AGAINST B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) CELLS CAN BE GENERATED FROM HLA-MATCHED SIBLING DONORS: IMPLICATIONS FOR
ADOPTIVE IMMUNOTHERAPY
M. Hoogendoorn, J. Olde Wolbers, W.M. Smit, M.R. Schaafsma, R.M.Y. Barge, R. Willemze, J.H.F. Falkenburg (Leiden University Medical Center, Leiden, The Netherlands)

AML THERAPY

085	TREATMENT OF NEWLY DIAGNOSED PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA USING INTRAVENOUS ARSENIC TRIOXIDE B. George, V. Mathews, P. Balasubramaniam, R. Shaji, A. Srivastava, M. Chandy (Christian Medical College, Vellore, Tamilnadu, India)
086	SECONDARY ACUTE MYELOID LEUKEMIA: RESULTS OF CONVENTIONAL TREATMENTS. EXPERIENCE OF GIMEMA TRIALS L. Pagano, A. Pulsoni, M. Vignetti, M.E. Tosti, P. Falucci, P. Fazi, L. Fianci, A. Levis, A. Bosi, E. Angelucci, P. Coser, M. Caira, R. Foà, S. Amadori, F. Mandelli, G. Leone (Università Cattolica del Sacro Cuore, Rome, Italy)
087	RISK-ADAPTED THERAPY OF ADULT ACUTE MYELOID LEUKAEMIA (AML) INCLUDING MULTIPLE HD-ARA-C CYCLES WITH LOW-DOSE STEM CELL SUPPORT: EXCELLENT RESULTS FROM A SINGLE CENTRE R. Bassan, T. Intermesoli, A. Rambaldi, A. Rossi, E. Oldani, U. Giussani, P. Bellavita, T. Barbui (Ospedali Riuniti Bergamo, Bergamo, Italy)
088	CYTARABINE BASED REGIMENS IN ACUTE MYELOID LEUKEMIA: - ASSESSMENT AND COMPARABILITY OF TREATMENT INTENSITY - USE OF THE CONCENTRATION COEFFICIENT WEIGHTED AREA UNDER THE CURVE (N-AUC) J. Braess, M. Fiegl, I. Lorenz, I. Zimmermann, W. Hiddemann (Klinikum Grosshadern, Munich, Germany)
089	RELATIVE SURVIVAL RATES IN AML PATIENTS IN SWEDEN 1973 - 2000. WHAT IMPACT HAVE NEW TREATMENT STRATEGIES HAD ON SURVIVAL? A.E. Rangert, O. Landgren, P. Dickman, S.Y. Kristinsson, M. Björkholm (Karolinska hospital, Stockholm, Sweden)
090	THE TREATMENT COST AND SURVIVAL OF PATIENTS WITH ACUTE LEUKEMIA -TAIWAN EXPERIENCE H.C. Hsu, H.H. Chen, H.C. Lu, J.P. Gau, W.K. Chau, C.H. Ho (Taipei-Veterans General Hospital, Taipei, Taiwan)
091	THE COMBINATION OF 2-CDA, CYTARABINE, MITOXANTRONE AND G-CSF (CLAG-M) AS INDUCTION THERAPY IN RESISTANT AND RELAPSED ACUTE MYELOID LEUKEMIA - PHASE II STUDY OF POLISH ADULT LEUKEMIA GROUP (PALG) A. Wrzesien-Kus, A. Wierzbowska, E. Lech-Maranda, A. Sobczak-Pluta, J. Holowiecki, S. Kyrcz-Krzemien, S. Grosicki, A. Dmoszynska, A. Hellmann, K. Kuliczkowski, T. Robak (Medical University, Lodz, Poland)

092	EFFICACY OF GEMTUZUMAB OZOGAMICIN (MYLOTARG) ON ATRA- AND/OR ARSENIC-RESISTANT ACUTE PROMYELOCYTIC LEUKEMIA (APL) CELLS A. Takeshita, K. Naito, K. Shinjo, H. Matsui, T. Horii, N. Shirai, M. Maekawa, K. Ohnishi, T. Naoe, R. Ohno (Hamamatsu University School of Medicine, Hamamatsu, Japan)
093	TREATMENT OF NEW CASES OF ACUTE PROMYELOCYTIC LEUKAEMIA BY ARSENIC TRIOXIDE G. Ghavamzadeh, A. Ghavamzadeh, K. Alimoghaddam, R. Hosseini, N. Aghdami, M. Jahani, Sh. Rostami, H. Ghaffari, Y. Mortazavi, S.A. Mossavi, B. Bahar, M. Irvani, A. Khodabandeh (Hematology, Oncology and BMT Research Centre, Tehran, Iran)
094	ACUTE LEUKEMIA - CLINICAL REGISTER (ALERT) IN THE CZECH REPUBLIC 1996-2004 K. Indrak (University Hospital, Olomouc, Czech Republic)
095	SAFETY PROFILE OF ZARNESTRA(TM) (TIPIFARNIB) IN PATIENTS WITH RELAPSED AND REFRACTORY ACUTE MYELOGENOUS LEUKEMIA (AML) J-L. Harousseau, J. Reiffers, B. Löwenberg, X. Thomas, F. Huguet, P. Fenaux, R. Stone, J. Lancet, A. Thibault (Hôtel Dieu, Nantes, France)
096	DRUG EXPOSURE IN A PHASE 2 STUDY OF PATIENTS WITH RELAPSED AND REFRACTORY ACUTE MYELOGENOUS LEUKEMIA (AML) TREATED WITH ZARNESTRA(TM) (TIPIFARNIB) J-L. Harousseau, J. Reiffers, R. Löwenberg, X. Thomas, F. Huguet, P. Fenaux, R. Stone, J. Lancet, A. Thibault (Hôtel Dieu, Nantes, France)
097	EFFICACY OF LOW-DOSE ALL-TRANS RETINOIC ACID IN THE TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA S. Cagirgan, M. Pehlivan, M. Hekimgil, M. Tombuloglu (Ege University Medical School, Izmir, Turkey)
098	ATTITUDE TOWARDS REMISSION INDUCTION (RI) FOR ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) AND SURVIVAL. ANALYSIS FROM THE SWEDISH ADULT ACUTE LEUKEMIA REGISTRY G. Juliusson, The Swedish Acute Leukemia, R. Billström, A. Gruber, E. Hellström-Lindberg, M. Höglund, K. Karlsson, D. Stockelberg, A. Wahlin, M. Åström, C. Arnesson, E. Holmberg, K. Nordenskjöld, J. Carstensen (Lund University Hospital, Lund, Sweden)
099	EFFICACY AND TOXICITY OF FLAI VS ICE FOR INDUCTION TREATMENT OF NEWLY DIAGNOSED AML PATIENTS, YOUNGER THAN 60 YEARS M. Malagola, G. Martinelli, D. Russo, D. Damiani, A. De Vivo, A. Candoni, R. Fanin, P.P. Piccaluga, P. Avanzini, G. Gugliotta, A. Zaccaria, F. Lauria, P. Mazza, M. Gobbi, M. Baccarani (Inst. of Hematology and Medical Oncology, Bologna, Italy)

100	ATTENUATED FLAIG REGIMEN IN ELDERLY PATIENTS WITH HIGH RISK ACUTE MYELOID LEUKEMIA OR MYELODYSPLASIA C. Ceretto, F. Marmont, E. Audisio, M.A. Ciocca Vasino, A. Busca, M. Falda, F. Locatelli, S.F. Salvi, L.A. Levis, T.A. Tonso, G.E. Gallo (Ospedale San Giovanni Battista, Torino, Italy)
101	FLUDARABINE, ARABYNOSIL CYTOSINE AND IDARUBICIN (FLAI), A COMBINATION OF NON MDR-RELATED DRUGS FOR TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA M. Malagola, D. Damiani, D. Russo, G. Martinelli, A. Candoni, A. Michelutti, A. De Vivo, N. Testoni, P. Mazza, M. Gobbi, A. Zaccaria, F. Lauria, R. Fanin, G. Visani, M. Baccarani (Inst. of Hematology and Medical Oncology, Bologna, Italy)
102	THE ROLE OF ADENOSINE AND ADENOSINE KINASE IN ACUTE MYELOID LEUKEMIAS WITH METHYLTHIOADENOSINE PHOSPHORYLASE (MTAP) INACTIVATION M. Schmid, K. Lehmann, H. Döhner (University of Ulm, Ulm, Germany)
103	5-YEAR SURVIVAL OF ACUTE MYELOID LEUKEMIA IN ITALY: RESULTS FROM THE EUROCARE-3 STUDY COMPARED TO GIMEMA MULTICENTRIC PROSPECTIVE TRIALS P. Fazi, M. Vignetti, A. Verdecchia, F. Paoloni, R. De Angelis, F. Mandelli (University “La Sapienza”, Roma, Italy)
104	CYTOREDUCTION RATE AFTER HYDROXIUREA PRE-TREATMENT IS AN INDEPENDENT PROGNOSTIC FACTOR FOR COMPLETE REMISSION IN ADULT AML M. Vignetti, P. Fazi, M. Sborgia, G. Meloni, A. Tabilio, A. Chiarenza, V. Liso, E. Angelucci, S. Galimberti, S. Magrin, A. Camera, L. Melillo, D. De Blasi, F. Ronco, M.C. Petti, F. Mandelli (University La Sapienza, Roma, Italy)
105	TREATMENT OF OLDER AML PATIENTS WITH LOW-DOSE 5-AZA-2’-DEOXYCYTIDINE (DECITABINE) M. Lübbert, P.W. Wijermans, B. Rüter, H. Henî (University of Freiburg Medical Center, Freiburg, Germany)
106	ALL-TRANS-RETINOIC ACID (ATRA) AND VALPROIC ACID (VPA) COMBINATION INDUCE TERMINAL DIFFERENTIATION IN AML BLASTS C. Garcia, M.Z. Garcia-Casado, J. Cervera, A. Valencia, J.C. Pajuelo, L. Senent, M.L. Perez-Sirvent, F. Gomis, A. Sempere, S. Cantero, M.L. Marty, M.A. Sanz (Hospital Universitario La Fe, Valencia, Spain)
107	ROLE OF CONSOLIDATION THERAPY IN ADULTS WITH HIGH RISK ACUTE MYELOID LEUKEMIA AGED UP TO 60 YEARS: RESULTS OF A PROSPECTIVE MULTICENTER TRIAL A. Ganser, J. Krauter, D. Hoelzer, O.G. Ottmann, H. Martin, M. Lübbert, J. Finke, W. Heit, W. Fiedler, D. Hossfeld, L. Kanz, G. Schlimok, H. Kirchner, A. Raghavachar, W. Brugger, G. Heil (Hannover Medical School, Hannover, Germany)

CHRONIC MYELOID LEUKEMIA

108	CHARACTERIZATION OF GENOMIC DELETION OF 5’ ABL AND 3’ BCR IN DER (9) CHROMOSOME IN CHRONIC MYELOID LEUKEMIA AND RESPONSE TO IMATINIB MESYLATE T.K. Saikia, C. Baisane, P.S. Amare-Kadam, K. Satam, N. Kabre, H. Jain, P.M. Parikh, C.D. Deshmukh (Tata Memorial Hospital, Mumbai, Bombay, India)
109	IMATINIB RESTORES PLASMACYTOID DENDRITIC CELL FUNCTION IN CHRONIC MYELOID LEUKEMIA PATIENTS M. Mohty, E. Jourdan, N. Ben Mami, D. Blaise, N. Vey, G. Damaj, D. Olive, B. Gaugler (Institut-Paoli-Calmettes, Marseille, France)
110	DOSE-ADJUSTMENT OF IMATINIB BASED ON PLASMA LEVEL MEASUREMENT IN A PATIENT WITH CML M. Heizmann, N. Widmer, L.A. Decosterd, A. Tobler, E. Oppliger Leibundgut (University hospital of Basel, Basel, Switzerland)
111	ON THE EXPECTED SURVIVAL ADVANTAGE OF IMATINIB OVER IFN IN CHRONIC PHASE CML PATIENTS M. Pfirrmann, J. Hasford (University of Munich, München, Germany)
112	TARGETING OF MCL-1 WITH ANTISENSE OLIGONUCLEOTIDES COUNTERACTS GROWTH AND VIABILITY OF CML CELLS: ROLE OF MCL-1 AS A NOVEL BCR/ABL-DEPENDENT TARGET IN CHRONIC MYELOID LEUKEMIA K.J. Aichberger, M.M. Mayerhofer, S. Florian, H. Skvara, M.T. Krauth, C. Akgul, S. Derdak, W.F. Pickl, V. Wacheck, E. Selzer, B.P. Monia, P. Valent, C. Sillaber (Vienna General Hospital, Vienna, Austria)
113	ALPHA-1-ACID GLYCOPROTEIN SHOWS INCREASED BINDING TO IMATINIB AT NEW HIGHER DOSES RECENTLY PROPOSED S.C. Paterson, K.D. Smith (University of Strathclyde, Glasgow, United Kingdom)
114	CLINICAL SAFETY OF IMATINIB: A PROSPECTIVE STUDY OF POSSIBLE CLINICAL EFFECTS OF INHIBITION OF OTHER TYROSINE KINASES IN PATIENTS TREATED FOR CHRONIC-PHASE CML J.F. Seymour, A.P. Grigg, M. Hertzberg, J. Matthews, K. Taylor, N. Guzzo-Pernell, A.K. Mills, M. Copeman, K. Lynch, T.P. Hughes (Peter MacCallum Institute, Melbourne, Australia)
115	SEMI-SYNTHETIC HOMOHARRINGTONINE FOR PATIENTS WITH CML IN ACCELERATED PHASE RESISTANT TO IMATINIB J.M. Goldman, J. Kaeda, J.P. Robin, J.F. Apperley, D. Marin (Imperial College /Hammersmith Hospital, London, United Kingdom)
116	AN INTERNATIONAL STUDY TO STANDARDIZE THE DETECTION OF BCR-ABL TRANSCRIPTS FROM STABILIZED PERIPHERAL BLOOD PREPARATIONS BY QUANTITATIVE RT-PCR M.C. Mueller, G. Saglio, F. Lin, H. Pfeifer, R.D. Press, R.R. Tubbs, P. Paschka, E. Gottardi, S.G. O’Brien, O.G. Ottmann, H. Stockinger, M. Ben-Am, L. Wieczorek, K. Merx, U. Schwindel, R. Hehlmann, A. Hochhaus (III. Medizinische Universitaetsklinik, Mannheim, Germany)

117	ANALYSIS OF IMATINIB THERAPY IN 300 PATIENTS WITH BCR-ABL POSITIVE LEUKEMIAS: EVALUATION OF RESPONSE AND RESISTANCE T. Lahaye, U. Berger, B. Riehm, S. Kreil, M.C. Müller, K. Merx, P. Paschka, U. Schwindel, C. Schoch, H. Gschaidmeier, R. Hehlmann, A. Hochhaus (III. Med. Klinik, Klinikum Mannheim, Mannheim, Germany)
118	THE INFLUENCE OF ARSENIC TRIOXIDE ON THE CLONOGENIC CAPACITY OF BONE MARROW IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC PHASE CML.